ELAN: Elanco Animal Health Incorporated $23.98
52-wk High $27.72
📌 Investment Snapshot
- 💰 Price & Valuation: Trading at $23.98, below its 50-day SMA, with a P/E of N/A due to negative EPS.
- 📈 Latest Quarter: Q4 FY25 revenue reached $1.1B, marking a robust +12.2% YoY growth, though EPS was N/A.
- 🔑 #1 Catalyst: Sustained strong revenue growth in the animal health market, coupled with potential for improved profitability.
- 🎯 Consensus: BUY rating from 13 analysts, with a mean target of $29.00, indicating +20.9% upside.
| 📍 Entry Zone | $22.00 or below | 🛑 Stop-Loss | $19.50 |
| 📋 Adjust If | RSI drops below 30 or MACD turns strongly bearish. | ||
The Investment Case — Why Now?
Elanco Animal Health is currently navigating a period of strategic growth, evidenced by its +12.2% YoY revenue increase in Q4 FY25. This momentum, particularly in the competitive animal health sector, suggests underlying strength despite today’s -5.66% price dip. With a consensus ‘BUY’ rating and a +20.9% upside target, the market sees potential for recovery and continued expansion.
However, the primary concern remains Elanco’s profitability, with a negative EPS (TTM) of $-0.47 and an N/A P/E ratio. The company’s ability to transition from revenue growth to sustained positive earnings will be critical. Failure to achieve this could undermine investor confidence and limit upside, despite strong top-line performance.
Company Overview
| Label | Value |
|---|---|
| Company | Elanco Animal Health Incorporated |
| Ticker / Exchange | ELAN / NYSE |
| Sector / Industry | Healthcare / Drug Manufacturers – Specialty & Generic |
| CEO | S. C. Tipton |
| Founded / HQ | 1954 / Greenfield, Indiana |
| Index Membership | S&P 500 |
Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| ELAN | (This stock) | N/A |
| S&P 500 Avg | S&P 500 Avg | 21.0x |
| UNH | UnitedHealth Group Incorporate | 20.8x |
| JNJ | Johnson & Johnson | 21.4x |
| LLY | Eli Lilly and Company | 39.5x |
| PFE | Pfizer, Inc. | 19.8x |
Price Action & Technicals
$23.98
-4.0%
+8.6%
-13.56%
Elanco’s price of $23.98 is currently below its 50-day SMA ($24.58) but comfortably above the 200-day SMA ($20.18), indicating a short-term pullback within a longer-term uptrend. Both the 14-day RSI at 38.1 and MACD at -0.131 suggest neutral momentum, with no immediate overbought or oversold signals. The stock’s position at 37.2% within the Bollinger Bands, leaning towards the lower band, could point to continued short-term weakness.
Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q4 FY25 | $1.1B | N/A | +12.2% |
| Q3 FY25 | $1.1B | $-0.07 | +10.4% |
| Q2 FY25 | $1.2B | $0.02 | +4.8% |
| Q1 FY25 | $1.2B | $0.13 | -1.0% |
Growth Drivers — What Moves the Stock
- Pet Health Segment Growth: The increasing humanization of pets drives demand for advanced animal health products. Elanco’s focus on companion animal pharmaceuticals and vaccines positions it for continued market share expansion.
- Innovation Pipeline: A robust R&D pipeline for new veterinary medicines and diagnostics is crucial. Successful product launches can significantly boost revenue and market penetration, especially in high-growth therapeutic areas.
- Emerging Markets Expansion: Growth in developing economies with rising pet ownership and livestock production presents significant opportunities for Elanco to expand its global footprint and diversify revenue streams.
Smart Money & Institutional Positioning
Institutional Holdings (Top 5)
| Institution | Shares (K) |
|---|---|
| Dodge & Cox Inc. | 79,084K |
| FMR, LLC | 52,196K |
| Vanguard Group Inc | 48,059K |
| Blackrock Inc. | 46,335K |
| Primecap Management Comp | 46,214K |
Holdings reflect most recent 13F (45-day lag). QoQ change not available.
Short Interest
| Short % of Float | Days to Cover |
|---|---|
| 4.19% | 3.3 |
With a short interest of 4.19% and 3.3 days to cover, Elanco exhibits low short interest, indicating limited bearish conviction among short sellers.
Key Risk Factors — Risk Matrix
Economic Downturn Impact: A significant economic slowdown could reduce discretionary spending on pet care and impact livestock production, directly affecting Elanco’s sales.
~$10B impact
Intense Market Competition: The animal health sector is highly competitive, with established players and new entrants vying for market share, potentially pressuring pricing and margins.
~$8B impact
Regulatory Hurdles & Approvals: Delays or failures in obtaining regulatory approvals for new products can significantly impact Elanco’s pipeline and future revenue streams.
~$12B impact
Profitability & Debt Challenges: Persistent negative EPS and a substantial debt load could hinder investments in growth and make the company vulnerable to rising interest rates or market volatility.
~$15B impact
Guidance & Wall Street View
Recent Analyst Actions
| Firm | Rating | Price Target | Date | Action |
|---|---|---|---|---|
| Morgan Stanley | Equal-Weight | $24.00 | 2026-02-25 | Maintain |
| Keybanc | Overweight | $29.00 | 2026-02-25 | Maintain |
| Leerink Partners | Outperform | $30.00 | 2026-02-24 | Maintain |
| JP Morgan | Overweight | $28.00 | 2026-02-19 | Maintain |
| Piper Sandler | Overweight | $30.00 | 2026-01-22 | Upgrade |
Consensus Price Target Distribution
| High Target | Mean Target | Low Target | Total Analysts | Consensus Rating |
|---|---|---|---|---|
| $32.00 | $29.00 | $20.00 | 13 | BUY |
The analyst consensus for Elanco is a strong ‘BUY’ from 13 analysts, with a mean price target of $29.00. This implies a significant +20.9% upside from the current price, despite a target range from $20.00 to $32.00 indicating some divergence in outlook.
Bull vs Bear — Probability-Weighted Scenarios
Bull Case
- Successful new product launches and robust demand in the pet health segment drive accelerated revenue growth beyond expectations.
- Operational efficiencies and cost management initiatives lead to a quicker-than-anticipated return to sustained profitability and positive EPS.
Implied Price Target: $32.00
Base Case
Elanco continues its moderate revenue growth trajectory, with gradual improvements in profitability. The company manages its debt effectively, and new product introductions contribute steadily to sales, aligning with analyst expectations.
Implied Fair Value: $29.00
Bear Case
- A deeper economic downturn or increased competition severely impacts demand for animal health products, leading to revenue stagnation or decline.
- Regulatory setbacks, higher-than-expected R&D costs, or persistent operational inefficiencies prevent the company from achieving profitability, leading to further losses.
Implied Downside Target: $20.00
Disclaimer & Hashtags
This Veqtio analysis is for informational and educational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. All data is sourced from publicly available information and believed to be accurate but is not guaranteed.
All active positions and their real-time performance are tracked on our Investment Log.
#ELAN #ElancoAnimalHealth #USStocks #StockAnalysis #Veqtio #Healthcare #DrugManufacturers #AnimalHealth